Related Experiment Video

Updated: Feb 8, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.5K

Combined angiotensin receptor and neprilysin inhibition therapy for heart failure

Becky N Lu1, Lindsay E Davis

  • 1At the time this article was written, Becky N. Lu was a student at Midwestern University College of Pharmacy in Glendale, Ariz. Lindsay E. Davis is an associate professor at Midwestern University. The authors have disclosed no potential conflicts of interest, financial or otherwise.

JAAPA : Official Journal of the American Academy of Physician Assistants
|June 30, 2018
PubMed

Insights

The FDA approved sacubitril/valsartan for heart failure treatment. This angiotensin-receptor-neprilysin inhibitor, studied in PARADIGM-HF, shows promise for patients with reduced ejection fraction.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic symptomatic heart failure (stage C) with reduced left ventricular ejection fraction (LVEF ≤35%) remains a significant clinical challenge.
  • Current treatment guidelines focus on neurohormonal blockade, but further therapeutic advancements are needed.

Purpose of the Study:

  • To discuss the FDA approval of sacubitril/valsartan, an angiotensin-receptor-neprilysin inhibitor.
  • To review the findings of the PARADIGM-HF clinical trial regarding this novel heart failure therapy.

Main Methods:

  • The PARADIGM-HF trial was a large-scale, randomized, double-blind, controlled study.
  • It compared sacubitril/valsartan to enalapril in patients with symptomatic heart failure and LVEF ≤35%.

Main Results:

  • Sacubitril/valsartan significantly reduced the risk of cardiovascular death and heart failure hospitalization compared to enalapril.
  • The drug demonstrated a favorable safety profile.

Conclusions:

  • Sacubitril/valsartan represents a new therapeutic class for managing chronic symptomatic heart failure with reduced LVEF.
  • The PARADIGM-HF trial provides robust evidence supporting its efficacy and safety.

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
368
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
978
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
927
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.7K